Nasopharyngeal carcinoma (NPC), a malignancy that develops in the upper section of the throat behind the nose, occurs in fewer than one person out of 100,000 worldwide each year. Locally advanced ...

Nasopharyngeal cancer refers to a relatively uncommon malignancy that begins in the nasopharynx—the upper section of the throat located behind the nose and above the back of the mouth. To understand ...

Please provide your email address to receive an email when new articles are posted on . Researchers found nearly identical 3-year PFS data among the two cohorts. Grade 3 and 4 short-term toxic effects ...

Positive opinion for TEVIMBRA in combination with chemotherapy as a first-line treatment of nasopharyngeal cancer (NPC) based on results of RATIONALE-309 study demonstrating statistically significant ...

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium Patients with American Joint Committee ...

DelveInsight's, “Nasopharyngeal Cancer Pipeline Insight” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Nasopharyngeal Cancer pipeline landscape. It covers the ...

Researchers are continuing to study nasopharyngeal carcinoma (NPC) to understand how it develops and what it responds to. Their goal is to provide better outcomes and possible prevention. NPC is a ...

Treatments for metastatic or recurrent nasopharyngeal carcinoma (NPC) may include chemotherapy, radiation, surgery, targeted drug therapy, and immunotherapy. NPC is a cancer that occurs in the head ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA® (tislelizumab), in combination with ...